4-氯-6-戊基氨基嘧啶 | 941294-44-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-6-戊基氨基嘧啶
• 英文名称: 6-Chloro-N-pentylpyrimidin-4-amine
• CAS: 941294-44-6
• 化学式: C₉H₁₄ClN₃
• 分子量: 199.68
• InChiKey: RAURQKJGNFOGEM-UHFFFAOYSA-N

物化性质

• 沸点：
  328.0±22.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

文献信息

• [EN] PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES<br/>[FR] DERIVES D'AMINOPYRIMIDINE A DISUBSTITUTION 4,6 ACTIFS SUR LE PLAN PHARMACEUTIQUE EN TANT QUE MODULATEURS DES PROTEINE KINASES
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2005026129A1

  公开（公告）日：2005-03-24

  The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furhtermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

  本发明涉及4,6-二取代氨基嘧啶衍生物及其药学上可接受的盐，以及这些衍生物作为药学活性剂的使用，特别是用于预防或治疗包括机会性感染、朊病毒病、免疫性疾病、自身免疫性疾病、双相情感障碍和临床障碍、心血管疾病、细胞增殖性疾病、糖尿病、炎症、移植排斥、勃起功能障碍、神经退行性疾病和中风的传染性疾病，以及包含至少一种所述的4,6-二取代氨基嘧啶衍生物及其药学上可接受的盐的药物组合物。此外，本发明还涉及所述4,6-二取代氨基嘧啶衍生物作为蛋白激酶抑制剂的使用，以及包含至少一种以固定形式存在的所述4,6-二取代氨基嘧啶衍生物的介质，以及使用所述介质来富集、纯化和/或耗尽与固定化的4,6-二取代氨基嘧啶衍生物结合的核苷酸结合蛋白。
• Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
  申请人：Choidas Axel

  公开号：US20070191344A1

  公开（公告）日：2007-08-16

  The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

  本发明涉及4,6-二取代氨基嘧啶衍生物和/或其药学上可接受的盐，这些衍生物的用途为药物活性剂，尤其用于预防和/或治疗传染病，包括机会性感染、朊病、免疫性疾病、自身免疫性疾病、双相和临床障碍、心血管疾病、细胞增殖性疾病、糖尿病、炎症、移植排斥、勃起功能障碍、神经退行性疾病和中风，以及含有至少一种上述4,6-二取代氨基嘧啶衍生物和/或其药学上可接受的盐的药物组合物。此外，本发明涉及使用所述4,6-二取代氨基嘧啶衍生物作为蛋白激酶的抑制剂，以及包含至少一种所述4,6-二取代氨基嘧啶衍生物的固定形式的介质，以及使用所述介质富集、纯化和/或去除与固定的4,6-二取代氨基嘧啶衍生物结合的核苷酸结合蛋白。
• PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES
  申请人：GPC Biotech AG

  公开号：EP1678147A1

  公开（公告）日：2006-07-12
• US8084457B2
  申请人：——

  公开号：US8084457B2

  公开（公告）日：2011-12-27